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ABSTRACT
The pregnane X receptor (PXR), or nuclear receptor (NR) 1I2, is
a ligand-activated NR superfamily member that is enriched in
liver and intestine in mammals. Activation of PXR regulates the
expression of genes encoding key proteins involved in drug
metabolism, drug efflux, and drug transport. Recent mechanistic
investigations reveal that post-translational modifications
(PTMs), such as phosphorylation, play a critical role in modulating the bimodal function of PXR-mediated transrepression and
transactivation of target gene transcription. Upon ligand binding,
PXR undergoes a conformational change that promotes dissociation of histone deacetylase–containing multiprotein corepressor protein complexes while simultaneously favoring recruitment
histone acetyl transferase–containing complexes. Here we describe a novel adenoviral vector used to deliver and recover
recombinant human PXR protein from primary cultures of hepatocytes. Using liquid chromatography and tandem mass spectrometry we report here that PXR is phosphorylated at amino
acid residues threonine 135 (T135) and serine 221 (S221).
Biochemical analysis reveals that these two residues play an

Introduction
Ligand activation of pregnane X receptor (PXR) facilitates
phase I (oxidative metabolism) (Kliewer et al., 1998; Lehmann
et al., 1998), phase II (conjugative metabolism) (Sonoda et al.,
2002; Chen et al., 2003; Xu et al., 2009; Staudinger et al.,
2010), and phase III (transport and efflux) metabolic pathways (Geick et al., 2001; Staudinger et al., 2001; Guo et al.,
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important regulatory role in the cycling of corepressor and
coactivator multiprotein complexes. These data further our
foundational knowledge regarding the specific role of PTMs,
namely phosphorylation, in regulating the biology of PXR.
Future efforts are focused on using the novel tools described
here to identify additional PTMs and protein partners of PXR in
primary cultures of hepatocytes, an important experimental
model system.
SIGNIFICANCE STATEMENT
Pregnane X receptor (PXR), or nuclear receptor 1I2, is a key
master regulator of drug-inducible CYP gene expression in liver
and intestine in mammals. The novel biochemical tools described in this study demonstrate for the first time that in cultures
of primary hepatocytes, human PXR is phosphorylated at
amino acid residues threonine 135 (T135) and serine 221
(S221). Moreover, phosphorylation of PXR promotes the transrepression of its prototypical target gene CYP3A4 through
modulating its interactions with coregulatory proteins.

2002; Kast et al., 2002). Two important PXR target genes
whose gene products participate in first-pass metabolism
include CYP3A4 (Kliewer et al., 1998; Lehmann et al., 1998)
and multidrug resistance 1 (Owen et al., 2004; Burk et al.,
2005; Cerveny et al., 2007; Satsu et al., 2008). The CYP3A4
enzyme is responsible for the oxidative metabolism of approximately 50% of all clinically prescribed medications (Guengerich, 1999), whereas P-glycoprotein 1 (P-gp1), the product of the
multidrug resistance 1 gene, is an ATP-dependent broadly
selective drug efflux pump (Hodges et al., 2011). The promiscuous nature of PXR activation is therefore mirrored in the
broad selectivity that characterizes the respective diverse
substrate specificities of both CYP3A4 and P-gp1. Through
induction of CYP3A4 and P-gp1 activity, particularly in intestine, PXR activation plays a critical role in tumor-acquired
drug resistance (Chen et al., 2007) and clinically important

ABBREVIATIONS: DBD, DNA-binding domain; GRIP1, glucocorticoid receptor-interacting protein 1; hPXR, human PXR; IMAC, immobilized metal
affinity chromatography; IRES, internal ribosomal entry sequence; LBD, ligand-binding domain; LC-MS/MS, liquid chromatography–tandem mass
spectrometry; Luc, luciferase; MOI, multiplicity of infection; NCoR, NR corepressor 1; NR, nuclear receptor; NRID, NR-interaction domain; PBP,
peroxisome proliferator-activated receptor-binding protein; P-gp1, P-glycoprotein 1; PTM, post-translational modification; PXR, pregnane X
receptor; SMRT, silencing mediator of retinoid and thyroid hormone receptor; SRC, steroid receptor coactivator; Rif, rifampicin; rt-QPCR, real-time
quantitative polymerase chain reaction; RXRa, retinoid X receptor a; XREM, xenobiotic response element.
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drug-drug, herb-drug, and food-drug interactions (Moore et al.,
2000; Ding and Staudinger, 2005a; Staudinger et al., 2006).
Similar to other nuclear receptor (NR) superfamily members, PXR activation can serve as a negative regulator of the
inflammatory response (Cheng et al., 2010, 2012; Kittayaruksakul et al., 2013; Sun et al., 2015). In fact, patients
suffering from irritable bowel syndrome can be treated with
a gut-specific PXR agonist, rifaximin, to reduce the inflammatory symptoms associated with this disease (Cheng et al.,
2010). PXR activation is important in other human diseases,
including inflammatory liver disease (Sun et al., 2015), inflammatory bowel disease (Shah et al., 2007; Cheng et al.,
2010, 2012), intrahepatic cholestasis (Xie et al., 2001; Goodwin
et al., 2003; Kakizaki et al., 2009, 2011; Geenes et al., 2011),
Type 2 diabetes (Hukkanen et al., 2014), and numerous
cancers (Kotiya et al., 2016; Wen et al., 2018). Therefore,
understanding the precise molecular mechanisms that regulate PXR biology is critical in developing new therapeutic
strategies to alter the course of these diseases.
The NR corepressor (NCoR) and the silencing mediator of
retinoid and thyroid hormone receptor (SMRT) proteins
comprise a family of transcription factor–scaffolding and
transcriptional corepressor proteins involved in the formation
of multiprotein histone deacetylase–containing protein complexes on the promoters of specific genes encoding inflammatory response proteins and drug-metabolizing enzymes
(Perissi et al., 2008; Ghisletti et al., 2009). Several studies
indicate a preferential association of PXR with SMRT (Johnson et al., 2006; Konno et al., 2009; Li et al., 2009), whereas
other studies indicate that NCoR can associate with PXR in
multiprotein corepressor complexes (Ding and Staudinger,
2005c; Lichti-Kaiser et al., 2009a,b). Somewhat paradoxically,
the strength of PXR association with SMRT is increased by the
presence of ligands (Konno et al., 2009; Li et al., 2009).
The major coactivator proteins implicated in PXR-mediated
transactivation include ligand-dependent steroid receptor
coactivator (SRC) family members SRC1 and glucocorticoid
receptor-interacting protein 1 (GRIP1) as well as peroxisome
proliferator-activated receptor-binding protein (PBP). Understanding the precise molecular mechanisms that govern
circulation of coregulatory protein exchange in response to
xenobiotic stimuli and pathogenic challenge is critical for
understanding the biology of PXR-initiated drug-drug interaction, drug toxicity, and tumor-acquired drug resistance.
In the current study, we use a novel adenovirus-mediated
recombinant PXR expression, purification, and recovery system used in conjunction with a liquid chromatography–
tandem mass spectrometry (LC-MS/MS)-based proteomic
strategy (Fig. 1A). Using this experimental approach, we
identify specific sites of phosphorylation of recombinant
human PXR recovered from primary cultures of hepatocytes.
To examine the biologic outcome of the identified site-specific
phosphorylation of the human PXR protein, we constructed
phosphomimetic mutants T135D and S221D as well as the
phosphodeficient mutant T135A. The mutational analysis
presented here indicates that modification of PXR at these
sites decreases strength of interaction with retinoid X receptor
a (RXRa), SRC1, GRIP1, and PBP while simultaneously
increasing the strength of PXR interaction with SMRT and
NCoR. Taken together, these data indicate that phosphorylation of PXR plays a key role in modulating PXR biology
through alterations in coregulatory protein-cofactor cycling.
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Materials and Methods
Chemicals and Plasmids. Rifampicin (Rif) was purchased from
Sigma-Aldrich, St. Louis, MO. All other reagents, including culture
medium for primary hepatocytes and mammalian cell lines, were
purchased from Fisher Scientific (St. Louis). Human PXR wild-type
and mutant constructs were fused to the VP16 transcriptional
activation domain by subcloning into the pVP16 expression vector
(Clontech, Mountain View, CA) at EcoRI and BamHI restriction
enzyme sites. The GAL4-SRC1, GAL4-GRIP1, GAL4-PBP, GAL4NCoR, and GAL4-SMRT expression vectors were constructed as
previously described (Synold et al., 2001; Ding and Staudinger,
2005a,c; Ding et al., 2006). To generate the GAL4-RXRa ligandbinding–domain (LBD) expression vector, the cDNA-encoding human
RXRa was inserted into the GAL4 expression vector using BamHI and
EcoRI restriction sites. The pFR-LUC GAL4-dependent luciferase
reporter gene, which is responsive to GAL4-fusion proteins, is
commercially available (BD Biosciences, San Jose, CA). The CYP3A4
reporter plasmid xenobiotic response element (XREM)-luciferase
(Luc) was previously described (Goodwin et al., 1999). The construction of the adenoviral expression construct encoding human PXR [Ad(His)6-PXR-3X-FLAG] was described previously (Cui et al., 2015).
Briefly, this novel adenovirus expresses both GFP and an engineered
form of human PXR, with both under the control of an internal
ribosomal entry sequence (IRES) (Fig. 1A). This experimental approach allowed us to monitor transduction efficiency, toxicity, and cell
morphology. As a negative control group, we used blank unprogrammed adenovirus (∅ = GFP only), whereas the experimental
group received virus programmed with GFP plus recombinant human
PXR, with both under the control of the IRES.
Site-Directed Mutagenesis. The identified phosphorylation
sites of PXR (T135, S221) were mutated to an aspartic acid (D) as
a phosphomimetic mutation or to an alanine (A) as a phosphodeficient mutation. The mutant pCMV-FLAG-hPXR expression vectors
were generated by site-directed mutagenesis with the use of the
QuikChange Mutagenesis system (Stratagene, La Jolla, CA).
Primer sequences used for site-directed mutagenesis are shown in
Table 1.
Hepa1-6 Cell Culturing and Viral Transduction. The Hepa16 cell line was used because of its proven utility in studies of hepatic
gene expression and liver biochemistry (Darlington et al., 1980) and
because of the fact that this mouse hepatoma–derived cell line does not
express detectable levels of PXR (Cui et al., 2015). Briefly, cells were
cultured in Dulbecco’s modified Eagle’s medium, 10% FBS, and
penicillin-streptomycin under standard conditions in 3-cM wells in
six-well dishes. Cells at 80–90% confluence were transduced (MOI =
10) with either blank virus (∅ = GFP only) or virus that was
programmed to express modified PXR. Cells were treated with either
vehicle (0.1% DMSO) of Rif (10 mM) for 24 hours. Total RNA was
isolated, and real-time quantitative polymerase chain reaction (rtQPCR) was performed to determine expression levels of Cyp3a11 as
described (Staudinger et al., 2003).
Mammalian Two-Hybrid System. The mammalian two-hybrid
system analysis was performed in 96-well plates using CV-1 cells plated
at 7000 cells/well. Transfection mixtures contained the GAL4-dependent
reporter gene pFR-LUC (20 ng), GAL4-cofactor NR-interaction domain
(NRID) (20 ng), VP16-PXR (10 ng), pSV–b-galactosidase (40 ng)
(Promega, Madison, Wi), and pBluescript (20 ng) per well. The next
day transfected cells were drug-treated for 24 hours. All compounds were
added to the culture medium as 1000X stocks dissolved in DMSO.
Luciferase and b-galactosidase activities were determined using the
Dual-Light Kit per the manufacturer’s instructions (Applied Biosystems,
Foster City, CA).
Isolation and Culturing of Primary Hepatocytes. Primary
hepatocytes were isolated from Sprague-Dawley rats at the age of
10–12 weeks with a standard collagenase perfusion procedure as
previously described (Staudinger et al., 2003). Potential sex differences were evaluated, and identical results were obtained from both
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Fig. 1. Adenoviral vector, cell morphology, GFP protein expression, and Ad-(His)6-PXR-(3X-FLAG) biologic function. Cells were observed and recorded
48 hours post-transduction with the novel adenoviral expression vector (A) using both bright-field and fluorescence microscopy (B) to visualize
transduction efficiency and cell viability. (C). Hepa1-6 cells were transduced with blank virus (∅ 2 GFP) or Ad-(His)6-PXR-(3X-FLAG) for 48 hours (MOI
= 10), and cells were treated with either vehicle (0.1% DMSO) or Rif (10 mM) for an additional 24 hours. rt-QPCR was performed, and Cyp3a11 gene
expression levels were determined (n = 3). Data are expressed as fold induction 6 S.D. compared with 18S ribosomal RNA expression. Asterisk (****)
indicates statistically significant induction (P # 0.001). Mag., magnification.

male and female rats. The representative results were acquired from
male rats.
Nuclei and Cytosol Fraction Separation. Primary rat hepatocytes were transduced with the Ad-(His)6-PXR-3X-FLAG recombinant
virus (MOI = 10) and were cultured for an additional 48 hours posttransduction. Transduced hepatocytes were harvested in 1.5 ml PBS
containing a cocktail of protease inhibitors (A32965; Fisher) and
centrifuged at 240g for 10 minutes at 4°C. Cell pellets were lysed by
adding approximately 5-pellet volumes of hypotonic buffer (10 mM Tris,
pH 7.7; 1.5 mM MgCl2; and 1 mM dithiothreitol), and the cell lysates
were centrifuged at 106g for 10 minutes at 4°C. The supernatant was
saved and was labeled as the cytosol fraction, and the pellet was labeled
as the nuclear fraction and was subsequently resuspended under strong
denaturing conditions for isolation of human PXR protein for LC-MS/MS
analysis using immobilized metal affinity chromatography (IMAC).

Cell-Based Cobalt-Bead Affinity PXR Pull-Down Assay. Posttranslationally modified PXR was purified and enriched from
primary cultured rat hepatocytes as previously described (Staudinger et al., 2011). Briefly, 10-cM dishes containing primary
cultures of hepatocytes or Hepa1-6 cells were harvested using
1 ml of a strong denaturing lysis buffer, 6 M Guanidine-Cl (pH 8),
according to specified experimental treatment. The whole-cell
lysates were then applied to 30 ml of TALON Metal Affinity Resin
(ClonTech, Palo Alto, CA) cobalt beads and incubated on a rotor at
room temperature for 2 hours with shaking. The gathered proteins
were collected via centrifugation and washed twice with lysis buffer,
three times with 8 M Urea buffer (pH 6.5), and once with 1 PBS.
Proteins were removed from the beads using 30 ml of 2 Laemmli
buffer and heated at 95°C for 10 minutes for subsequent Western
blot or LC-MS/MS analysis.

TABLE 1
Oligonucleotide primers used in site-directed mutagenesis
Amino Acid

T135
S221

Oligos for Mutagenesis to A

Left primer
Right primer
Left primer
Right primer

59
59
59
59

tgaacggacaggggctcagccactggg 39
cccagtggctgagcccctgtccgttca 39
ttgtagttccagacagcgccatcctccccccg 39
cggggggaggatggcgctgtctggaactacaa 39

Oligos for Mutagenesis to D

59
59
59
59

aagtgaacggacaggggatcagccactgggagtg 39
cactcccagtggctgatcccctgtccgttcactt 39
tttgtagttccagacatcgccatcctccccccgc 39
gcggggggaggatggcgatgtctggaactacaaa 39

PXR Protein Phosphorylation in Cultured Hepatocytes
Fluorescence Microscopy. Primary cultured hepatocytes were
transduced with blank virus (∅ = GFP only) or recombinant PXR that
has GFP under the control of an internal ribosomal entry sequence as
a marker of transduction efficiency. Twenty-four hours posttransduction, hepatocytes were washed once with 1 PBS. To
visualize, hepatocytes were washed three times with 1x PBS and
then maintained in Opti-MEM I Reduced Serum Media (Thermo
Fisher) during fluorescence protein image analysis. Fluorescent
proteins were imaged with a 30 phase-contrast objective, whereas
cells were excited at 400 nm to visualize GFP as a qualitative marker
of both cell morphology as well as viral transduction efficiency.
Western Blot Analysis. Western blot analysis was performed as
described previously (Xu et al., 2009). Antibodies used include the
mouse monoclonal anti-PXR antibody (H-11; Santa Cruz, Dallas, TX),
anti-GAL4 (DNA-binding domain), or VP16 monoclonal antibodies
(Upstate Biotechnology, Lake Placid, NY) and an anti-actin monoclonal antibody (MP Biomedicals, Irvine, CA).
Liquid Chromatography–Tandem Mass Spectrometry Analysis. The LC-MS/MS analysis for identification of PXR phosphorylation was performed as described previously (Cui et al., 2015).
Luciferase Reporter Gene Assay. The XREM-LUC and GAL4dependent luciferase reporter gene assays were performed as described previously (Ding and Staudinger, 2005c; Cui et al., 2016).
Briefly, CV-1 cells were seeded at 1  104 cells per well (n = 8) in
96-well plate and transfected using LipofectAMINE 2000. Twentyfour hours post-transfection, cells were treated with either vehicle
(0.1% DMSO) 10 mM Rif. The transfection efficiency was quantified
according to the activity of b-galactosidase. The relative fold change in
reporter gene luciferase units was normalized to b-galactosidase
values to reflect transfection efficiency among all experimental
groups, respectively.
Statistical Analysis. Data presented are expressed as the mean
6 S.D. Differences between treatment groups were evaluated by oneway ANOVA followed by Tukey’s multiple comparison test or by twoway ANOVA followed by Tukey’s multiple comparison test. Among
experimental groups, *P , 0.05, **P , 0.01, and ****P , 0.001
compared with the control cell population (vehicle treatment). Tukey’s
or Dunnett’s post hoc comparison test was used to determine
statistical differences between groups, and values of P , 0.05 (*),
P , 0.01 (**), and P , 0.001 (****) were considered statistically
significant.

Results
Recombinant PXR Expression Level, Recovery, and
Biologic Function. To determine the extent to which hepatocyte transduction was robust and cultured cells were
morphologically healthy, hepatocytes were visualized using
phase-contrast microscopy 24 hours post-transduction. The
LC-MS/MS experiments used three 15-cm collagen-coated
tissue culture plates of primary rat hepatocytes with approximately 20 million live cells per dish at plating for both the
control group (Ø = GFP 2 blank virus) and the experimental group transduced with Ad-(His)6-hPXR-(3X-FLAG).
Figure 1A depicts the relationship between the GFP marker
gene, the IRES, and the human PXR transgene delivered
using viral transduction. Note that the construct delivers
either GFP alone (Ø = GFP 2 blank virus) or GFP plus the
Ad-(His)6-hPXR-(3X-FLAG) transgene. Cell morphology and
GFP protein expression were observed and recorded 48 hours
post-transduction using both phase-contrast and fluorescence microscopy to broadly visualize transduction efficiency
and cell viability. There was no dramatic visual difference in
cell viability between the experimental group and control
group (Fig. 1B).
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We next sought a suitable PXR-deficient model system to
examine the transactivation capacity of our recombinant form
of human PXR. The expression and activity level of PXR is
undetectable in the murine Hepa1-6 hepatoma cell line, and
hence the induction of PXR target genes is absent in this
model system (unpublished data). The rt-QPCR analysis
revealed that Rif-inducible Cyp3a11 gene expression was
present only in the PXR viral-transduced experimental group
(Fig. 1C). Identical results were obtained utilizing PXR
knockout hepatocytes as an experimental model system (unpublished data). Collectively, the data in Figure 1 indicate
that the recombinant form of (His)6-hPXR-(3X-FLAG) human
PXR protein is biologically functional. Additionally, these data
indicate that this novel viral vector can be delivered with high
efficiency to both primary hepatocytes as well as to immortalized cell lines without producing marked visual evidence of
toxicity in cell-based experimental model systems.
Identification of PXR Phosphorylation Sites Using
LC-MS/MS in Primary Hepatocytes. There are several
critical limitations of phosphopeptide-mapping experiments
using the LC-MS/MS approach. One limitation is the relatively low endogenous expression and low stoichiometry of the
phosphomodified protein of interest. Moreover, the inherent
LC-MS/MS machine-specific detection limits can also produce
difficulties in detection of phosphomodified peptides. To overcome these obstacles, we used an adenoviral delivery method
to achieve high-level expression and recovery of recombinant
human 6X-histidine–tagged PXR [(His)6-PXR-(3X-FLAG)].
Because we were primarily interested in the PTMs of nuclear
PXR protein, we isolated intact nuclei using a hypotonic buffer
in the presence of high concentrations of both protease and
phosphatase inhibitors. Our overall experimental approach
is outlined in Figure 2. After biochemical fractionation of
cytosolic and nuclear fractions, the recombinant nuclear PXR
protein was isolated using IMAC under strong denaturing
buffer conditions. The resulting protein isolates were resolved
using 4%–15% gradient SDS-PAGE and subjected to Coomassie staining (Fig. 3A, left panel). This experimental approach
achieved high-level PXR enrichment and a relatively low level
of background or nonspecific protein binding. Western blot
analysis using a monoclonal antibody against human PXR
further confirmed the expression and efficient recovery of the
recombinant and likely modified PXR protein (Fig. 3A, right
panel). The total coverage achieved in our LC-MS/MS analysis
of IMAC-enriched tryptic peptides derived from recombinant
(His)6-PXR-(3X-FLAG) was approximately 60% (unpublished
data). Using this approach, we identified two novel phosphorylation sites in the PXR protein to include threonine 135
(T135) and serine 221 (S221). The mass spectrometric parameters for the identification of PXR phosphorylation sites are
listed in Figure 3B. It is worth noting here that we always
detected T135 together with S221 phosphorylation in the
primary faster-migrating PXR-immunoreactive band, whereas
the slightly slower migrating PXR-immunoreactive band was
reliable and repeatedly contained the S221 phosphorylation
event alone (Fig. 3A).
Constitutive Phosphorylation Inhibits the Transactivation Capacity of PXR. To examine the biologic
significance of the two novel identified sites of PXR phosphorylation, we constructed two phosphomimetic mutant PXR
proteins: T135D and S221D. We also constructed a T135
phosphodeficient mutant (T135A), and all three mutant
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transcriptional events require the recruitment of a variety of
positive and negative regulatory proteins in a highly coordinated and orchestrated manner. The precise molecular
mechanisms that control the promoter-dependent circulation of coregulatory multiprotein complexes likely involve
numerous finely tuned PTMs interacting with each other in
a yet-to-be discovered manner. The extent to which any
specific phosphorylation event contributes to the coregulatory protein exchange with respect to PXR is currently
unknown or is not well-characterized.
We therefore sought to construct a mammalian two-hybrid
system to assess the effect of these specific phosphomimetic
and phosphodeficient mutations in PXR to potentially examine any alterations in their coregulatory protein-protein

Fig. 2. Experimental strategy for adenoviral expression and recovery of
human PXR protein from primary cultures of hepatocytes for LC-MS/MS
analysis. Three 15-cm dishes of primary cultured rat hepatocytes were
transduced with Ad-(His)6-PXR-3X-FLAG (MOI = 10) for 48 hours. Cells
were treated with either vehicle (0.1% DMSO) or Rif (10 mM) for an
additional 24 hours. Cells were lysed in a hypotonic buffer, and the nuclear
fraction was isolated. Isolated nuclei were lysed under strong denaturing
conditions, and nuclear PXR was isolated using IMAC as described in
Materials and Methods.

proteins were inserted into a mammalian expression vector
that uses the cytomegalovirus promoter to drive expression in
transfected cell lines. Unfortunately, we were unable to
generate the phosphodeficient mutation at S221 or the double
phosphodeficient mutant because of a technical difficulty
in modifying a guanine-enriched region on template DNA.
We thus sought to determine the extent to which these three
mutant PXR proteins are altered in their ability to support
either basal or ligand-inducible transactivation capacity using
the CYP3A4-derived XREM-LUC reporter gene assays in
CV-1 cells.
Mammalian expression vectors encoding wild-type or the
indicated mutant PXR proteins were cotransfected together
with the XREM-LUC reporter gene into cultured CV-1 cells.
Twenty-four hours post-transfection, cells were treated with
either vehicle (0.1% DMSO) or Rif (10 mM) for an additional
24 hours. The relative basal expression and fold induction of
reporter gene levels were determined. With respect to T135,
both the phosphomimetic (T135D) and the phosphodeficient
(T135A) mutations somewhat reduced basal expression of
PXR-dependent reporter gene activity. In contrast, the S221D
phosphomimetic mutation produced a very highly significant
reduction in basal reporter gene activity (Fig. 4A), indicating
a strong repression of basal PXR transactivation capacity in
this cell line. The S221D phosphomimetic mutation also
produced the most significant repression of Rif-inducible
reporter gene activity (Fig. 4B). The results obtained here
are in line with previous findings that PXR phosphorylation
leads to a suppressive effect of its transactivation capacity
(Ding and Staudinger, 2005a,c; Lichti-Kaiser et al., 2009a,b;
Pondugula et al., 2009a,b).
Validation of the Mammalian Two-Hybrid System
Protein-Protein Interaction Panel. PXR-mediated

Fig. 3. SDS-PAGE analysis of isolated nuclear protein and LC-MS/MS
analysis of the recombinant human PXR protein. (A) Isolated nuclei were
lysed under strong denaturing conditions, and following IMAC protein
isolates were resolved using 4%–20% SDS-PAGE. Coomassie staining was
performed (left panel) and Western blot analysis was performed (right
panel) using an anti-PXR monoclonal antibody (H-11; Sant Cruz). (B) LCMS/MS analysis was performed on immunoreactive PXR protein as
indicated (arrows). Two novel PXR phosphorylated peptides were detected
as indicated in the figure (bottom panel). Threonine 135 (T135) phosphorylation on human PXR was identified according to the assignment of multiple
product ions (b and y ions) in the MS2 scan of the precursor ion at m/z 897.44
to the PXR tryptic peptide sequence, with a mass addition of 80 at the
threonine residue (phosphate group). Serine 221 (S221) phosphorylation
on human PXR was identified according to the assignment of multiple
product ions (b and y ions) in the MS2 scan of the precursor ion at m/z
972.42 to the PXR tryptic peptide sequence, with a mass addition of 80 at
the serine residue. Veh, vehicle.

PXR Protein Phosphorylation in Cultured Hepatocytes

Fig. 4. Phospho-deficient and phosphomimetic mutations of human PXR
in the XREM-LUC reporter gene assay. Cultures of CV-1 cells were
transfected with plasmids encoding wild-type and mutant PXR proteins as
indicated. (A) Twenty-four hours post-transfection, the basal levels of
XREM-LUC reporter gene activity were measured. (B) After an additional
24 hours of treatment with 10 mM Rif, the inducible levels of XREM-LUC
reporter gene activity were measured. All data (n = 4) are normalized to
the vehicle-treated wild-type PXR group (n = 4) and, further, relative to
b-galactosidase activity. Data are reported as the mean 6 S.D., in which
P , 0.05, P , 0.01 (**), and P , 0.001 (****). WT, wild type.

interaction profile. To accomplish this, we fused the GAL4
DNA-binding domain (DBD) to the NRID, respectively, from
cDNA sequences derived from RXRa, SRC1, GRIP1, PBP,
NCoR, and SMRT proteins. Using this experimental approach, we have created a custom panel of known PXRassociated coregulatory proteins for experimental examination. We next fused cDNAs encoding wild-type and mutant
full-length PXR proteins in-frame to the strong ligandindependent transcriptional activation domain derived from
the herpes viral protein, VP16. All constructs described here
were subsequently verified by DNA sequence analysis on both
strands to ensure the integrity of their respective openreading frames.
This two-hybrid strategy renders activation of the GAL4dependent pFR-LUC reporter gene reliant upon proteinprotein interaction between these two hybrid fusion proteins.
In other words, the strength of protein-protein interaction is
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described by the amount of reporter gene activity in this model
system. In addition to examining basal strength of proteinprotein interaction, this experimental approach also allows for
the direct examination of the effects of ligand on the strength
of interaction between PXR and our custom panel of wellknown coactivator and corepressor proteins.
Western blot analysis using a monoclonal anti-GAL4 antibody against cell extracts from CV-1 cells transfected indicated that all GAL4-cofactor NRID fusion proteins were
expressed at their predicted mass, respectively (Fig. 5B).
Western blot analysis with a monoclonal antibody directed
against PXR indicates that all of the PXR proteins were
expressed at equivalent levels at the appropriate size when
expressed in CV-1 cells by transient transfection (Fig. 5C).
Our initial efforts focused on an examination of the strength
of interaction between GAL4-RXRa, GAL4-SRC1, GAL4GRIP1, GAL4-PBP, GAL4-NCoR, and GAL4-SMRT and
wild-type VP16-PXR. Twenty-four hours post-transfection,
CV-1 cells were treated either with 0.1% DMSO (vehicle) or
Rif (10 mM) for an additional 24 hours. The reporter gene
activity was measured in cell extracts using standard methods. The wild-type VP16-PXR fusion protein interacted
strongly with all tested GAL4-NRID coregulatory proteins in
the absence of ligand (Fig. 5D). As expected, treatment with
Rif increased the strength of interaction between PXR and
coactivator proteins, including SRC1, GRIP1, and PBP. Also
as expected, the addition of Rif resulted in decrease in the
strength of PXR interaction and both RXRa and NCoR. In
contrast, the strength of interaction between VP16-PXR and
GAL4-SMRT (NRID) was increased by ligand activation.
Although this is a somewhat counterintuitive observation,
since SMRT is a corepressor protein, this result is consistent
with other studies of PXR-SMRT protein-protein interaction
(Johnson et al., 2006; Konno et al., 2009).
PXR-RXRa Heterodimerization. The heterodimerization of PXR and RXRa is the first wave of action for ligandmediated transactivation of PXR target genes. A previous
study in our laboratory demonstrated that phosphorylation at
certain sites on PXR impairs the heterodimerization of PXRRXRa (Lichti-Kaiser et al., 2009a). We therefore next sought
to determine the extent to which the phosphomutant PXR
proteins were able to undergo heterodimerization with RXRa.
CV-1 cells were cotransfected with the expression vector
encoding the GAL4-RXRa-LBD fusion protein together with
the wild-type and mutant forms of VP16-PXR. Twenty-four
hours post-transfection, cells were treated with 0.1% DMSO
(Vehicle) or Rif (10 mM) for an additional 24 hours. The
luciferase activity of the GAL4-dependent reporter gene was
measured to evaluate the relative strength interaction between PXR and RXRa. Both T135D and S221D phosphomimetic mutations reduce the ability of PXR to dimerize with
RXRa, whereas the T135A phosphodeficient mutation increased the strength of interaction between these two proteins
(Fig. 6).
Strength of Association with Coactivator NRIDs. We
next sought to determine the extent to which the wild-type and
mutant PXR proteins are able to physically associate with
NRIDs derived from well-known canonical PXR-associated
coactivator proteins SRC1, GRIP1, and PBP. Both the phosphomimetic and phosphodeficient mutations at position T135 slightly
but significantly reduced the strength of ligand-independent
interaction with SRC1, whereas the ligand-dependent increase
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Fig. 5. Validation of a panel of PXR-associated coregulatory proteins in the mammalian two-hybrid system. (A) The NRID derived from known PXRassociated coregulatory proteins, including its obligate dimeric partner RXRa; coactivator proteins SRC1, GRIP1, and PBP; and corepressor proteins
SMRT and NCoR, were fused to the GAL4 DBD. (B) Expression levels of the GAL4-cofactor NRID were confirmed using anti-GAL4 antibody in Western
blot analysis. (C) Expression levels of the wild-type and mutant PXR VP16-fusion proteins were confirmed using anti-PXR antibodies in Western blot
analysis. All constructs described here were analyzed for their open-reading frame integrity using DNA sequence analysis, respectively. (D) The
interaction between wild-type VP16-PXR and GAL4 cofactors was analyzed. Forty-eight hours post-transfection, reporter gene activity was determined
in the presence and absence (0.1% DMSO) of 10 mM Rif for an additional 24 hours. The blank (2) represents CV-1 cells transfected with luciferase and
b-gal reporter genes only treated with vehicle or Rif as indicated. WB- Western Blot, UAS)5- Upstream Activating Sequence. Data are normalized to
b-galactosidase and are reported as the avg. 6 S.D. (n = 4), in which P , 0.05 (*), P , 0.01 (**), and P , 0.001 (****).

in interaction was largely preserved. In contrast, the S221D
phosphomimetic mutant strongly inhibited the strength of
both ligand-independent and ligand-dependent interaction
with coactivator protein SRC1 (Fig. 7A). Similar to SRC1,
the S221D strength of interaction with coactivator NRIDs
derived from GRIP1 (Fig. 7B) and PBP was most significantly diminished (Fig. 7C). It is notable that the T135D
phosphomimetic mutation did not have very significant
impact on the strength of ligand-dependent association with
SRC1-, GRIP1-, or PBP-NRIDs.
Strength of Association with SMRT- and NCoRNRIDs. Together, the SMRT and NCoR proteins collectively form a small family of transcriptional corepressor
proteins. Current dogma suggests that SMRT is the preferred partner for PXR (Johnson et al., 2006; Konno et al.,
2009), whereas in some instances PXR interaction with
NCoR is implicated in PXR-mediated transrepression phenomena (Ding and Staudinger, 2005a,b,c). In an effort to
determine the extent to which the two identified phosphorylation events alter PXR association with the NRIDs derived from either SMRT or NCoR, respectively, we next

examined their interaction using our mammalian twohybrid analysis.
Both the phosphodeficient (T135A) and phosphomimetic
(T135D) mutations produced highly significant reductions in
the strength of interaction between PXR and the SMRT-NRID
(Fig. 8A). Moreover, the addition of Rif to the system had no
significant effect on the strength of association between either
of the two T135 mutant proteins (T135A and T135D) and the
SMRT-NRID. In contrast, the S221D phosphomimetic mutation modestly but significantly strengthened basal PXRSMRT-NRID protein-protein interaction in the absence of
ligand. Of note, the strength of association between S221D
and SMRT was strongly reduced by the addition of ligand, an
effect opposite to that of the ligand-dependent increase in the
strength of interaction between the SMRT-NRID and wildtype PXR.
Neither phosphodeficient (T135A) nor phosphomimetic
(T135D) mutant PXR proteins differed significantly from
ligand-independent and ligand-dependent interaction with
interaction with the NCoR-NRID when compared with wildtype PXR (Fig. 8B). Remarkably, the phosphomimetic S221D
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Fig. 6. Strength of interaction between PXR and its obligate dimeric
partner RXRa. Wild-type and indicated mutant PXR expression vectors
were transfected along with GAL4-RXRa LBD and the XREM-LUC
reporter gene. Twenty-four hours post-transfection, cells were treated
with Rif (10 mM) or vehicle (0.1% DMSO) for an additional 24 hours. Fortyeight hours post-transfection, reporter gene activity was determined.
Data are normalized to b-galactosidase and are reported as the avg. 6
S.D. (n = 4), in which P , 0.001 (****). WT, wild type.

mutation produced a very strong and highly significant
increase in the strength of interaction with NCoR-NRID.

Discussion
NR family members are evolutionarily conserved transcription factors that share a similar modular structural arrangement comprised of an N-terminal DBD, a C-terminal LBD,
and a flexible hinge region located in between the DBD and
LBD regions of the protein. Gene repression by nuclear
receptors is a spatial and temporal event that is precisely
carried out by the circulation of specific coregulatory proteins
to include NcoR- and SMRT-containing multiprotein complexes. Ligand-mediated gene activation is accompanied by
dissociation of the corepressor multiprotein complex followed
by the recruitment of coactivator multiprotein protein complexes, whereas termination of gene expression commands the
proteasomal degradation of the NR coactivator machinery.
This last event is accompanied by the physical interaction of
the promoter with a newly synthesized NR-corepressor multiprotein complex. This process is therefore cyclic in nature and
is thought to be required for maximal gene expression by NR
superfamily members in general (Perissi and Rosenfeld,
2005). Post-translational modifications often regulate and
fine tune the biology of NR proteins in a collaborative fashion.
PXR expression is highly enriched in liver and intestine in
mammals (Kliewer et al., 1998; Lehmann et al., 1998). In
comparison with many other NR superfamily members, the
PXR LBD has a relatively large volume and an extremely
flexible ligand-binding pocket (Watkins et al., 2003; Watkins
et al., 2001). This large flexible LBD enables the accommodation of a very broad structural spectrum of compounds to
trigger PXR transactivation capacity. Hence, PXR is activated
by a myriad of steroid hormones, bile acids, environmental
toxins, numerous prescription drugs, key constituents of
herbal remedies, several pesticides, and additional xenobiotic

Fig. 7. Strength of interaction between PXR and coactivator proteins.
Wild-type and indicated mutant PXR expression vectors were transfected
along with (A) GAL4-SRC1, (B) GAL4-GRIP1, and (C) GAL4-PBP together
with the XREM-LUC reporter gene. Twenty-four hours post-transfection,
cells were treated with Rif (10 mM) or vehicle (0.1% DMSO) for an
additional 24 hours. Forty-eight hours post-transfection, reporter gene
activity was determined. Data are normalized to b-galactosidase activity
and are reported as the avg. 6 S.D. (n = 4), in which P , 0.001 (****). WT,
wild type.
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Fig. 8. Strength of interaction between PXR and corepressor proteins.
Wild-type and indicated mutant PXR expression vectors were transfected
along with (A) GAL4-SMRT or (B) GAL4-NCoR together with the XREMLUC reporter gene. Twenty-four hours post-transfection cells were treated
with Rif (10 mM) or vehicle (0.1% DMSO) for an additional 24 hours. Fortyeight hours post-transfection, reporter gene activity was determined. Data
are normalized to b-galactosidase activity and are reported as the avg. 6
S.D. (n = 4), in which P , 0.05 (*), P , 0.01 (**), and P , 0.001 (****). WT,
wild type.

chemicals (Staudinger et al., 2001, 2006; Moore et al., 2002,
2003; Lichti-Kaiser and Staudinger, 2008).
After ligand binding, the PXR protein undergoes a conformational change that favors dissociation of the corepressor
complex followed closely by recruitment of histone acetyl
transferase–containing coactivator multiprotein complexes
to initiate full transcriptional activation of its target genes
(Lichti-Kaiser and Staudinger, 2008; Lichti-Kaiser et al.,
2009a,b). Multiple individual studies observe crosstalk between PTMs at the level of PXR, which regulates many aspects
of its biology. Previous studies from our laboratory demonstrate that SUMOylation of PXR can suppress inflammatory
gene activation and promote the recognition of ubiquitinated
PXR destined for proteasomal degradation (Cui et al., 2015).
PXR-mediated transcription activity involves a series of proteinprotein interaction events to include the heterodimerization of

PXR-RXRa and the circulation of coregulatory proteins. PXR
heterodimerization with RXRa is considered the first step in
response to ligand binding and is essential for subsequent
gene activation. It is well-established that site-specific phosphorylation of PXR contributes to the modulation of its
transactivation capacity through modulating a broad range
of its biologic activities to include heterodimerization with
RXRa, DNA-binding to its response element, and modulation
of coregulatory protein-protein interactions (Ding and Staudinger, 2005a,b,c; Lichti-Kaiser et al., 2009a,b; Pondugula
et al., 2009a,b; Doricakova et al., 2013). The ligand-dependent
dissociation of PXR from RXRa deserves further scrutiny in
light of the increasingly complex nature of the release of NRassociated corepressor protein complexes. We are mindful of
the fact that most of the specific phosphorylation events
targeting PXR examined to date have been determined to
function as negative effectors of PXR-transactivation capacity.
Several groups have used in vitro analysis to detect putative
sites of PXR phosphorylation that were subsequently analyzed in immortalized cell lines. A myriad of kinases have been
reported to drive phosphorylation of PXR to include 70-kDa
ribosomal S6 kinase (p70 S6K) (Lichti-Kaiser et al., 2009a;
Pondugula et al., 2009a,b), cyclic AMP-dependent protein
kinase A (Ding and Staudinger, 2005c; Lichti-Kaiser et al.,
2009a,b), protein kinase C (Ding and Staudinger, 2005c;
Lichti-Kaiser et al., 2009b), cyclin-dependent kinase 2 (Lin
et al., 2008; Sugatani et al., 2010, 2012; Elias et al., 2014), and
cyclin-dependent kinase 5 (Dong et al., 2010). All of these
previous studies relied primarily upon systematic in vitro
phosphorylation analysis followed by experiments in immortalized cell lines. It was our experimental goal in this study to
try to directly examine rather than infer PTMs of recombinant
PXR protein that was recovered from primary hepatocytes
rather than using in vitro or immortalized cell-line model
systems.
Utilizing LC-MS/MS–based proteomic approach is a trending and attractive experimental strategy to monitor PTMs.
However, because of the low stoichiometry of phosphorylation
in vivo and also because of the inherently low limit of detection
inherent in the LC-MS/MS approach, we have developed an
innovative adenoviral expression construct to achieve high
expression and subsequent recovery of PXR protein from
cultures of primary hepatocytes. This approach will allow us
to continue to examine the myriad of PTMs on PXR moving
forward in both cell-based and live animal models. The likely
involvement of numerous PTMs in regulating the PXR transactivation and transrepression capacity has been highlighted
in numerous recent studies (Lichti-Kaiser et al., 2009a,b; Hu
et al., 2010; Biswas et al., 2011; Elias et al., 2014; Cui et al.,
2015, 2016; Pasquel et al., 2016; Sugatani et al., 2016). The key
PTMs described to date that regulate PXR biology include
phosphorylation, acetylation, ubiquitination, and SUMOylation. Moreover, it is clear that the interactions between these
PTMs can further modulate receptor biology, such as with
phosphorylation-dependent SUMOylation and described interactions between acetylation and SUMOylation (Cui et al., 2015,
2016). Previous studies from our laboratory have demonstrated that increased cAMP-dependent protein kinase A
and protein kinase C signaling inhibits PXR transactivation
capacity through modulating PXR heterodimerization with
RXRa and with coregulatory proteins (Ding and Staudinger,
2005c; Lichti-Kaiser et al., 2009a,b).
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In the current study, we have identified two novel phosphorylation sites of PXR at T135 and S221. It is noteworthy
that the T135 amino acid residue is located in the hinge region
that connects DBD and LBD of PXR. The hinge region controls
the particular orientation of the DBD and LBD upon ligand
binding, which eventually leads to nuclear localization and
activation of PXR (McKenna et al., 1999; Nagy and Schwabe,
2004). Several lines of evidence suggested that phosphorylation at the hinge region of many nuclear receptors contributes
to their heterodimerization and transactivation capacity
(Delmotte et al., 1999; Blanquart et al., 2004). Importantly,
the S221 amino acid residue is located within the LBD of PXR.
The LBD of NRs is considered to be a molecular switch that,
when liganded, produces a conformational change that
transforms PXR from a repressive protein into a transcriptional activator by recruiting different coregulatory protein
complexes (Pawlak et al., 2012). However, unlike the LBD of
a canonical NR superfamily member, which is composed of
10 a helices and three b strands and forms a three-layer
sandwich; the LBD of PXR has two additional b1 and b19
strands. These additional strands are thought to adapt to
and therefore bind a broad spectrum of PXR ligands (Watkins et al., 2001; Xiao et al., 2002). This phenomenon has
been referred to as directed promiscuity (Chrencik et al.,
2005).
Our current investigation employing the phosphomimetic
and phosphodeficient mutant PXR proteins indicates that
PXR phosphorylation significantly impairs its transactivation
capacity, particularly phosphorylation at S221. In our view, it
is significant that the location of S221 is in the additional b19
strands of PXR LBD. Therefore, phosphorylation at this
particular serine may be involved in the feedback response
to terminate the ligand-activated PXR transactivation capacity to subsequently promote PXR-mediated transrepression.
In that respect, it is extremely interesting that the S221D
mutation strongly enhanced the association of PXR with the
NCoR corepressor protein, a well-characterized transrepressor of key inflammatory response genes. Therefore, PXR
phosphorylation at S221 may be a key step in clinically
observed drug-induced inhibition of the inflammatory response in liver and intestine (Shah et al., 2007; Cui et al.,
2015; Sun et al., 2015; Staudinger, 2019). In contrast, the
mutations at T135 significantly interrupt the PXR-SMRT
protein-protein interaction while showing comparatively low
or no significant effect upon PXR association with NCoR or
coactivator proteins RXRa, SRC1, GRIP1, and PBP. Collectively, these findings suggest that the phosphorylation of PXR
observed at position T135 likely involves alternative mechanisms or different biologic outcomes not involving
coregulatory protein circulation. It is now well-accepted
that phosphorylation suppresses PXR activity through interrupting its heterodimerization and interactions with coregulatory proteins. In response to specific cellular signals, PXR
phosphorylation inhibits its transcription activity through the
action of reducing the capability to form a heterodimer with
RXRa, disrupting the interaction between PXR and coactivator proteins and likely through affecting the translocation of
PXR into the nucleus.
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